NDAORALTABLET, FOR SUSPENSION
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination of lamivudine and zidovudine, two nucleoside reverse transcriptase inhibitors (NRTIs) used in antiretroviral therapy. The combination is indicated for HIV treatment and works by inhibiting reverse transcriptase to suppress viral replication. It is an oral tablet/suspension formulation developed by Cipla.
PRE_LAUNCH
Pre-launch stage indicates limited commercial infrastructure; career opportunities tied to launch planning, market entry strategy, and initial field build-out.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This pre-launch generic combination offers career opportunities in regulatory approval, manufacturing scale-up, and emerging-market commercialization rather than clinical innovation. Success depends on operational excellence, cost control, and government procurement strategy in resource-limited settings.
Regulatory Affairs ManagerSupply Chain Manager
Worked on LAMIVUDINE; ZIDOVUDINE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.